Discover undervalued stocks with Eulerpool.

Subscribe for $2

Regenxbio Stock RGNX

Price

0
Today +/-
-0
Today %
-0 %

Regenxbio stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Regenxbio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Regenxbio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Regenxbio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Regenxbio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Regenxbio Stock Price History

DateRegenxbio Price
10/7/20250 undefined
10/7/202510.58 undefined
10/6/202510.70 undefined
10/3/202510.31 undefined
10/2/202510.59 undefined
10/1/20259.75 undefined
9/30/20259.66 undefined
9/28/20259.85 undefined
9/25/20259.65 undefined
9/24/20259.36 undefined
9/24/20259.47 undefined
9/23/20258.95 undefined
9/22/20259.15 undefined
9/19/20258.92 undefined
9/19/20258.91 undefined
9/18/20259.27 undefined
9/17/20259.22 undefined
9/16/20259.09 undefined
9/15/20259.10 undefined
9/12/20259.21 undefined
9/11/20259.49 undefined
9/10/20259.62 undefined
9/9/20259.90 undefined
9/8/20259.36 undefined

Regenxbio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Regenxbio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Regenxbio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Regenxbio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Regenxbio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Regenxbio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Regenxbio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Regenxbio’s growth potential.

Regenxbio Revenue, EBIT and net profit per share

DateRegenxbio RevenueRegenxbio EBITRegenxbio Net Income
2030e830.24 M undefined0 undefined120.44 M undefined
2029e645.01 M undefined55.3 M undefined-7.57 M undefined
2028e480.63 M undefined-95.72 M undefined-81.05 M undefined
2027e382.74 M undefined-59.05 M undefined-77.82 M undefined
2026e254.95 M undefined-142.62 M undefined-121.49 M undefined
2025e253.14 M undefined-97.99 M undefined-122.24 M undefined
202483.33 M undefined-230.35 M undefined-227.1 M undefined
202390.24 M undefined-268.13 M undefined-263.49 M undefined
2022112.7 M undefined-262.9 M undefined-280.3 M undefined
2021470.3 M undefined160 M undefined127.8 M undefined
2020154.6 M undefined-119.2 M undefined-111.3 M undefined
201935.2 M undefined-149 M undefined-94.7 M undefined
2018218.5 M undefined88.1 M undefined99.9 M undefined
201710.4 M undefined-75.9 M undefined-73.2 M undefined
20164.6 M undefined-65.3 M undefined-63 M undefined
20157.6 M undefined-23.1 M undefined-23.8 M undefined
20146.1 M undefined-3.7 M undefined-4.8 M undefined
20136.1 M undefined-4.8 M undefined-5.8 M undefined

Regenxbio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
2013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
667410218351544701129083253254382480645830
--16.67-42.86150.002,080.00-83.94340.00205.19-76.17-19.64-7.78204.820.4050.3925.6534.3828.68
83.3383.3385.7175.0080.0095.4177.1476.6288.9451.7958.8959.0419.3719.2912.8310.217.605.90
5563820827118418585349000000
-5-4-23-63-7399-94-111127-280-263-227-122-121-77-81-7120
--20.00475.00173.9115.87-235.62-194.9518.09-214.41-320.47-6.07-13.69-46.26-0.82-36.365.19-91.36-1,814.29
25.425.425.426.429.936.636.737.343.943.243.7349.51000000
- - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Regenxbio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Regenxbio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (k)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (B)
201320142015201620172018201920202021202220232024
                       
1.11.1114.189.6160.8319.8296.2475.7457.4364.6275.26234.69
0.21.12.110.58.638.14332.428.124.7920.47
9008000000000000
000000000000
001.92.86.79.510.712.52923.334.9222.84
2.23118.193.4168337.9345531.2518.8416334.97278
000.59.31428.739.1120.3192.5206.8192.59171.31
0.30.3102.569.415.6150.8103.846.8391.9200.638.8710.18
00000234.23.32.31.50.70.47
000000000000
000000000000
00.20.20.61.13.45.96.68.58.46.846.03
0.30.5103.279.330.7205.9153177595.2417.3239187.99
000.220.170.20.540.50.711.110.830.570.47
                       
22.712.60000000000.01
00.010.270.280.370.590.630.670.930.971.021.19
-24.8-28.8-51.6-114.6-187.8-83-177.8-289.1-161.2-441.6-705.05-932.15
00-7000-700-700200-400-2,600-15,400-4,429-741
000000000000
-2.1-5.7216.8161.8183508.9450.2377.7764.3516.1311.74259.65
0.30.311.54.84.46.410.611.427.222.7922.8
0.21.13.28.19.616.427.348.466.552.856.7745.97
4.25.30.1001.3022.452.550.450.7234.42
02.40000000000
000000000000
4.79.14.39.614.422.133.781.4130.4130.4130.27103.19
000005.9000000
000000000000
000.21.31.26.914249219.1186.6131.96103.14
000.21.31.212.814249219.1186.6131.96103.14
4.79.14.510.915.634.947.7330.4349.5317262.23206.34
000.220.170.20.540.50.711.110.830.570.47
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Regenxbio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Regenxbio's financial health and stability.

Assets

Regenxbio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Regenxbio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Regenxbio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Regenxbio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-5-4-22-63-7399-94-111127-280-263
0000247891217
00000000000
21-350-7-5144014-10
0061522251266808678
00000000000
000003006110
-3-2-22-48-58104-107-54218-207-218
000-8-7-13-11-26-84-30-9
00-16319-4-27993122-406-11190
00-163272-266105149-32218200
00000000000
02000000000
202390852058722247
222390842048200195-28-34
0000000192-27-33-42
00000000000
-1053-292129-52687-248-62
-3-2.4-23-56.7-65.291.3-119.4-81134.7-238.2-228.37
00000000000

Regenxbio stock margins

The Regenxbio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Regenxbio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Regenxbio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Regenxbio's sales revenue. A higher gross margin percentage indicates that the Regenxbio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Regenxbio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Regenxbio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Regenxbio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Regenxbio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Regenxbio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Regenxbio Margin History

Regenxbio Gross marginRegenxbio Profit marginRegenxbio EBIT marginRegenxbio Profit margin
2030e59.72 %0 %14.51 %
2029e59.72 %8.57 %-1.17 %
2028e59.72 %-19.92 %-16.86 %
2027e59.72 %-15.43 %-20.33 %
2026e59.72 %-55.94 %-47.65 %
2025e59.72 %-38.71 %-48.29 %
202459.72 %-276.43 %-272.54 %
202358.76 %-297.12 %-291.99 %
202251.64 %-233.27 %-248.71 %
202188.99 %34.02 %27.17 %
202076.91 %-77.1 %-71.99 %
201976.7 %-423.3 %-269.03 %
201895.61 %40.32 %45.72 %
201783.65 %-729.81 %-703.85 %
201678.26 %-1,419.57 %-1,369.57 %
201580.26 %-303.95 %-313.16 %
201483.61 %-60.66 %-78.69 %
201395.08 %-78.69 %-95.08 %

Regenxbio Stock Sales Revenue, EBIT, Earnings per Share

The Regenxbio earnings per share therefore indicates how much revenue Regenxbio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Regenxbio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Regenxbio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Regenxbio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Regenxbio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Regenxbio Revenue, EBIT and net profit per share

DateRegenxbio Sales per ShareRegenxbio EBIT per shareRegenxbio Earnings per Share
2030e16.77 undefined0 undefined2.43 undefined
2029e13.03 undefined0 undefined-0.15 undefined
2028e9.71 undefined0 undefined-1.64 undefined
2027e7.73 undefined0 undefined-1.57 undefined
2026e5.15 undefined0 undefined-2.45 undefined
2025e5.11 undefined0 undefined-2.47 undefined
20241.68 undefined-4.65 undefined-4.59 undefined
20232.06 undefined-6.13 undefined-6.02 undefined
20222.61 undefined-6.09 undefined-6.49 undefined
202110.71 undefined3.64 undefined2.91 undefined
20204.14 undefined-3.2 undefined-2.98 undefined
20190.96 undefined-4.06 undefined-2.58 undefined
20185.97 undefined2.41 undefined2.73 undefined
20170.35 undefined-2.54 undefined-2.45 undefined
20160.17 undefined-2.47 undefined-2.39 undefined
20150.3 undefined-0.91 undefined-0.94 undefined
20140.24 undefined-0.15 undefined-0.19 undefined
20130.24 undefined-0.19 undefined-0.23 undefined

Regenxbio business model

Regenxbio Inc is a biopharmaceutical company that specializes in the development of AAV-based gene therapies for rare genetic diseases. The company was founded in 2009 in Maryland, USA and has since developed an impressive portfolio of therapy options. The history of Regenxbio Inc begins with the realization that gene therapies offer a promising way to treat rare genetic diseases for which there are currently no cures. However, at that time, there were still many technical and regulatory hurdles to overcome. Regenxbio took on these challenges and specialized in the development of adeno-associated viruses (AAV) as vectors for the transfer of therapeutic genes, as these viruses are ideally suited for this purpose. The business model of Regenxbio Inc is based on licensing its technology platform to other companies, which can then develop their own gene therapies. The company has already formed partnerships with major pharmaceutical companies such as AstraZeneca and Novartis, who utilize Regenxbio's technology platform to develop new therapy options for rare diseases. A significant aspect of Regenxbio Inc is the discovery and development of gene therapies for rare diseases. These include diseases such as choroideremia syndrome and mucopolysaccharidosis type I, among others. The company has already conducted clinical trials that have shown promising results and has received approval in the EU. Regenxbio aims to replace invasive and complicated treatments with gene therapy options. Additionally, Regenxbio Inc also offers services in the manufacturing of AAV-based gene therapies. The company supports other firms in the production and quality control of AAV vectors required for the manufacturing of gene therapies. This business sector plays a crucial role in the distribution of therapies to the market. The ultimate goal of Regenxbio Inc is to improve the quality of life for individuals suffering from rare genetic diseases through the development and commercialization of gene therapies. With innovative technologies and partnerships with other pharmaceutical companies, the company has already established an important role in the field of gene therapy development. Overall, the company has a very positive future outlook and will remain under observation in the healthcare industry. Regenxbio is one of the most popular companies on Eulerpool.com.

Regenxbio SWOT Analysis

Strengths

Regenxbio Inc has a strong portfolio of gene therapy products that have shown promising results in clinical trials. This positions the company as a leader in the field of gene therapy.

The company has a highly talented team of scientists and researchers who possess extensive expertise in gene therapy, giving them a competitive advantage in developing innovative treatments.

Regenxbio Inc has formed strategic partnerships with major pharmaceutical companies, providing them with access to additional resources, expertise, and potential distribution channels.

Weaknesses

One weakness of Regenxbio Inc is its heavy reliance on a limited number of product candidates. If any of these candidates fail in clinical trials or face regulatory hurdles, it could significantly impact the company's revenue and future prospects.

The company's success heavily depends on the regulatory environment for gene therapy, which is subject to change and uncertainty. This poses a risk to the company's ability to bring its products to market.

Opportunities

The growing demand for effective treatments in genetic diseases presents a significant opportunity for Regenxbio Inc. As the field of gene therapy continues to advance, the company has an opportunity to capture a larger market share.

Expanding partnerships within the healthcare industry can open doors for collaborative research and development, allowing Regenxbio Inc to access new technologies and potential markets.

Threats

One major threat to Regenxbio Inc is the intense competition in the gene therapy market. Other companies are also investing heavily in research and development, potentially resulting in similar or superior gene therapy products.

Uncertainty surrounding intellectual property rights and potential legal disputes pose a threat to the company's ability to protect and monetize its gene therapy technologies and products.

Regenxbio Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Regenxbio Revenue by Segment

Segmente20222021202020192018
License and royalty112.72 M USD470.35 M USD---
License---600,000 USD3.9 M USD

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Regenxbio Revenue by Segment

Segmente20222021202020192018
License and royalty--154.57 M USD35.23 M USD-

  • 3 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Regenxbio Revenue by Segment

Segmente20222021202020192018
License-----
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Regenxbio Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Regenxbio historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Regenxbio shares outstanding

The number of shares was Regenxbio in 2024 — This indicates how many shares 49.509 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Regenxbio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Regenxbio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Regenxbio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Regenxbio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Regenxbio.

Regenxbio latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-1.12 -1.38  (-22.99 %)2025 Q2
3/31/20250.49 0.12  (-75.63 %)2025 Q1
12/31/2024-1.17 -1.01  (13.65 %)2024 Q4
9/30/2024-1.14 -1.17  (-2.21 %)2024 Q3
6/30/2024-1.32 -1.05  (20.28 %)2024 Q2
3/31/2024-1.28 -1.33  (-3.57 %)2024 Q1
12/31/2023-1.3 -1.43  (-10.34 %)2023 Q4
9/30/2023-1.55 -1.41  (8.92 %)2023 Q3
6/30/2023-1.41 -1.66  (-17.51 %)2023 Q2
3/31/2023-1.57 -1.53  (2.39 %)2023 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Regenxbio stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

51

👫 Social

87

🏛️ Governance

17

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Regenxbio shareholders

%
Name
Stocks
Change
Date
9.64616 % Redmile Group, LLC4,775,717-19,0636/30/2025
8.61682 % BlackRock Institutional Trust Company, N.A.4,266,099348,7976/30/2025
6.91024 % The Vanguard Group, Inc.3,421,192-51,7966/30/2025
6.02961 % JP Morgan Asset Management2,985,20138,8196/30/2025
5.86059 % Fox (Allan Mark)2,901,5207,7685/30/2025
3.72386 % State Street Global Advisors (US)1,843,645777,5526/30/2025
3.49656 % BlackRock Financial Management, Inc.1,731,114637,9676/30/2025
3.24364 % Goldman Sachs & Company, Inc.1,605,893962,6156/30/2025
2.27943 % Geode Capital Management, L.L.C.1,128,52121,5756/30/2025
2.26780 % Dimensional Fund Advisors, L.P.1,122,763-24,9636/30/2025
1
2
3
4
5
...
10

Regenxbio Executives and Management Board

Mr. Kenneth Mills

(49)
Regenxbio Chairman of the Board (since 2009)
Compensation 5.92 M

Mr. Patrick Christmas

(53)
Regenxbio Executive Vice President, Chief Legal Officer
Compensation 3.44 M

Dr. Stephen Pakola

(55)
Regenxbio Executive Vice President, Chief Medical Officer
Compensation 3.31 M

Dr. Olivier Danos

(66)
Regenxbio Executive Vice President, Chief Scientific Officer
Compensation 2.99 M

Mr. Curran Simpson

(62)
Regenxbio President, Chief Executive Officer, Director (since 2015)
Compensation 2.95 M
1
2
3

Regenxbio Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ultragenyx Pharmaceutical Stock
Ultragenyx Pharmaceutical
SupplierCustomer0,870,980,900,890,830,80
Novartis Stock
Novartis
SupplierCustomer0,750,71-0,72-0,72-0,140,05
Clearside Biomedical Stock
Clearside Biomedical
SupplierCustomer0,630,830,690,750,770,42
Bayer Stock
Bayer
SupplierCustomer0,600,79-0,41-0,41-0,49-0,22
uniQure Stock
uniQure
SupplierCustomer0,590,930,890,660,820,55
Pfizer Stock
Pfizer
SupplierCustomer0,460,930,410,17-0,54-0,43
FUJIFILM Holdings Stock
FUJIFILM Holdings
SupplierCustomer0,320,500,550,440,59-0,08
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,310,61-0,35-0,33-0,70-0,59
Prevail Therapeutics, Inc. Stock
Prevail Therapeutics, Inc.
SupplierCustomer0,210,29
Sarepta Therapeutics Stock
Sarepta Therapeutics
SupplierCustomer0,080,730,860,830,490,19
1
2

Most common questions regarding Regenxbio

What values and corporate philosophy does Regenxbio represent?

Regenxbio Inc is a renowned biotechnology company specializing in the development of life-changing gene therapies for patients suffering from severe diseases. The company's core values revolve around innovation, scientific excellence, and patient-centric focus. Regenxbio Inc is dedicated to improving the lives of individuals by harnessing the power of gene therapy to address unmet medical needs. With a commitment to integrity, collaboration, and transparency, Regenxbio Inc strives to bring groundbreaking treatments to patients, build strong partnerships, and continuously push the boundaries of scientific discovery. Their corporate philosophy embodies a relentless pursuit of transformative therapies to revolutionize healthcare and provide hope for those in need.

In which countries and regions is Regenxbio primarily present?

Regenxbio Inc is primarily present in the United States.

What significant milestones has the company Regenxbio achieved?

Regenxbio Inc has achieved several significant milestones in its history. One notable milestone is the successful completion of a Phase I clinical trial for its lead product candidate, RGX-314. This novel gene therapy aims to treat wet age-related macular degeneration (AMD). Additionally, Regenxbio has entered into partnerships with renowned pharmaceutical companies, including Novartis and Audentes Therapeutics, to further expand its gene therapy platform. The company has also garnered regulatory approvals for its gene therapy products, including FDA breakthrough therapy designation for RGX-314. These achievements highlight Regenxbio's commitment to developing innovative gene therapies for various genetic disorders, including eye diseases.

What is the history and background of the company Regenxbio?

Regenxbio Inc. is a biotechnology company focused on the development and commercialization of gene therapy treatments. Founded in 2008, Regenxbio has grown into a leading player in the field of gene therapy, with a strong emphasis on adeno-associated virus (AAV) vector technology. The company has developed a proprietary NAV Technology Platform, which enables the precise and targeted delivery of therapeutic genes to specific cells in the body. Regenxbio has made significant strides in advancing gene therapy treatments for various genetic disorders, including ophthalmic, metabolic, and neurodegenerative diseases. As an innovative and pioneering company, Regenxbio is committed to revolutionizing the future of gene therapies.

Who are the main competitors of Regenxbio in the market?

The main competitors of Regenxbio Inc in the market include other gene therapy companies such as bluebird bio, Sangamo Therapeutics, uniQure, and Spark Therapeutics.

In which industries is Regenxbio primarily active?

Regenxbio Inc is primarily active in the biotechnology industry.

What is the business model of Regenxbio?

The business model of Regenxbio Inc is focused on developing and commercializing gene therapy treatments for various genetic diseases. Regenxbio utilizes its proprietary adeno-associated virus (AAV) gene delivery platform, which enables targeted and precise gene therapy delivery to specific cells in the body. This versatile platform allows Regenxbio to address a wide range of genetic disorders, including neurodegenerative diseases, metabolic disorders, and ophthalmic diseases. By leveraging their expertise in gene therapy and collaborating with partners, Regenxbio aims to bring effective and innovative treatments to patients with unmet medical needs.

What is the P/E ratio of Regenxbio 2025?

The P/E ratio cannot be calculated for Regenxbio at the moment.

What is the P/S ratio of Regenxbio 2025?

The P/S cannot be calculated for Regenxbio currently.

What is the Quality Investing of Regenxbio?

The Quality Investing for Regenxbio is 4/10.

What is the revenue of Regenxbio 2025?

The expected Regenxbio revenue is 253.14 M USD.

How high is the profit of Regenxbio 2025?

The expected Regenxbio profit is -122.24 M USD.

What is the business model of Regenxbio

Regenxbio Inc is a biopharmaceutical company focused on the development of gene therapies for rare genetic diseases. The company's business model is based on the discovery, development, and commercialization of innovative gene therapies to improve the lives of patients worldwide. Regenxbio was founded in 2009 and is headquartered in Rockville, Maryland (USA). As a pioneer in the field of gene therapy, the company has developed an extensive platform based on AAV vector technology. This platform allows Regenxbio to develop customized gene therapies and create new treatment options for patients with rare diseases. Regenxbio's research and development focuses on the identification and characterization of AAV vectors, each capable of transporting and expressing specific genes. Regenxbio has developed a wide range of AAV vectors tailored to the needs of patients with different conditions. The company has partnerships with numerous pharmaceutical and biotech companies such as Novartis, Alexion Pharmaceuticals, and Pfizer. These partnerships focus on the development of gene therapy solutions for various diseases such as cystic fibrosis, hemophilia, and Fabry disease. Regenxbio also has its own pipeline of gene therapy products in various stages of clinical development. Some of the products developed by Regenxbio include: - RGX-314: A gene therapy for the treatment of wet age-related macular degeneration (AMD). This therapy is based on the use of AAV8 vectors to transport the gene for the anti-VEGF antibody into the eye. - RGX-121: A gene therapy for the treatment of mucopolysaccharidosis type II (MPS II). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme iduronate-2-sulfatase (IDS) into the brain. - RGX-111: A gene therapy for the treatment of mucopolysaccharidosis type I (MPS I). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme alpha-L-iduronidase (IDUA) into the brain. - RGX-501: A gene therapy for the treatment of hemophilia A. This therapy is based on the use of AAV8 vectors to transport the gene for factor VIII into the liver. Regenxbio is on its way to becoming one of the leading companies in the gene therapy industry. The customized platform for gene therapy development, close collaboration with partners, and the company's own pipeline of gene therapy products should bring growth and success to the company in the future.

What is the Regenxbio dividend?

Regenxbio pays a dividend of 0 USD distributed over payouts per year.

How often does Regenxbio pay dividends?

The dividend cannot currently be calculated for Regenxbio or the company does not pay out a dividend.

What is the Regenxbio ISIN?

The ISIN of Regenxbio is US75901B1070.

What is the Regenxbio WKN?

The WKN of Regenxbio is A140E0.

What is the Regenxbio ticker?

The ticker of Regenxbio is RGNX.

How much dividend does Regenxbio pay?

Over the past 12 months, Regenxbio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regenxbio is expected to pay a dividend of 0 USD.

What is the dividend yield of Regenxbio?

The current dividend yield of Regenxbio is .

When does Regenxbio pay dividends?

Regenxbio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regenxbio?

Regenxbio paid dividends every year for the past 0 years.

What is the dividend of Regenxbio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regenxbio located?

Regenxbio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regenxbio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regenxbio from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.

When did Regenxbio pay the last dividend?

The last dividend was paid out on 10/7/2025.

What was the dividend of Regenxbio in the year 2024?

In the year 2024, Regenxbio distributed 0 USD as dividends.

In which currency does Regenxbio pay out the dividend?

The dividends of Regenxbio are distributed in USD.

All fundamentals about Regenxbio

Our stock analysis for Regenxbio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regenxbio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.